ApoGlyx
2 known investors
ApoGlyx develops first-in-class therapies based on aquaporin inhibitors, targeting inflammatory diseases such as acute pancreatitis. Its drug development work focuses on aquaporin protein channels implicated in inflammation, autoimmunity, cancer, diabetes, and malaria.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does ApoGlyx do?
- ApoGlyx develops first-in-class therapies based on aquaporin inhibitors, targeting inflammatory diseases such as acute pancreatitis. Its drug development work focuses on aquaporin protein channels implicated in inflammation, autoimmunity, cancer, diabetes, and malaria.
- Who are ApoGlyx's investors?
- ApoGlyx's investors include LU Innovation, Almi Invest.